stocktools
Offerings // Liminatus Pharma, Inc.

LIMN offering history

Every offering-related filing in Liminatus Pharma, Inc.’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 105 filings back to May 2, 2023.

Last executed offering
Jul 6, 2026
8-K — priced deal (shares or notes)
Last registration (announced)
Jun 24, 2026
S-1 — capacity, not a sale
Executed, last 12 months
4
424B pricings + 8-K 3.02 sales
Registered, last 12 months
2
S-1/S-3/F-series registrations
DateFilingWhat it means
Jul 6, 20268-K →EXECUTEDUnregistered share sale disclosed (8-K item 3.02)
Jun 24, 2026S-1 →REGISTEREDS-1 registration — capacity to sell shares, not a sale yet
Jun 3, 2026424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Jun 3, 20268-K →EXECUTEDUnregistered share sale disclosed (8-K item 3.02)
Feb 18, 2026424B4 →EXECUTEDFinal prospectus — offering priced (typical for IPOs and marketed share deals)
Feb 13, 2026EFFECT →EFFECTIVESEC declared a registration effective — selling can begin
Feb 11, 2026S-1 →REGISTEREDS-1 registration — capacity to sell shares, not a sale yet
Feb 9, 20268-K →EXECUTEDUnregistered share sale disclosed (8-K item 3.02)
Aug 13, 2025424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Aug 12, 2025EFFECT →EFFECTIVESEC declared a registration effective — selling can begin
Jul 28, 2025S-1/A →REGISTEREDS-1/A registration — capacity to sell shares, not a sale yet
Jul 17, 20258-K →EXECUTEDUnregistered share sale disclosed (8-K item 3.02)
Jun 24, 2025S-1 →REGISTEREDS-1 registration — capacity to sell shares, not a sale yet
May 6, 20258-K →EXECUTEDUnregistered share sale disclosed (8-K item 3.02)
Feb 7, 2025424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Feb 6, 2025EFFECT →EFFECTIVESEC declared a registration effective — selling can begin
Aug 12, 2024424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Aug 9, 2024EFFECT →EFFECTIVESEC declared a registration effective — selling can begin
LIMN offering-related filings from SEC EDGAR, newest first (capped at 40). Each links to the original document.

Two honest limits. (1) A 424B takedown can price shares or notes— EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.

Is a shelf active now? →Do they need money? →Red flags →Full LIMN workspace →
LIMN offering FAQ

When did LIMN last execute an offering?

Per SEC filings, Liminatus Pharma, Inc.'s most recent priced offering document is a 8-K filed 2026-07-06. Note a 424B takedown can price shares or notes (debt) — the linked document says which.

When did LIMN last announce or register an offering?

The most recent registration is a S-1 filed 2026-06-24. A registration is capacity to sell shares — not a sale.

Does an offering always mean dilution?

Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.